Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Oct 6, 2026 · Notice filed Oct 6, 2026
A Rapport Therapeutics officer told the SEC about a plan to sell $1.23M of Rapport Therapeutics shares around Oct 6, 2026. The filing says the shares were acquired as compensation. That is a tiny part of all Rapport Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider filing
Traded Oct 30 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 30 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
7 days before resultsTraded Oct 28 · filed 2 days later
A Rapport Therapeutics director paid $79K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
